开窗腔内主动脉修复术早期经验:近肾动脉与近肾/肾下动脉瘤的中远期结局
回顾性分析2012年4月至2017年4月单中心90例Zenith开窗支架腔内修复术(FEVAR),比较近肾动脉瘤(26例)与近肾/肾下动脉瘤(64例)的中远期结局。8年免于再干预率分别为67.4%与57.6%(P=0.93),总生存率分别为35.9%与42.3%(P=0.46),差异均无统计学意义。再干预率较高(27.8%),主要因内漏,多发生在术后2-3年内。
要点
- 近肾与近肾/肾下FEVAR的8年免于再干预和总生存无显著差异。
- 总体再干预率27.8%,近肾组26.9% vs 近肾/肾下组28.1%,主要因内漏。
- 研究样本量小、事件率低,不足以证明等效性,需长期监测。
核心结论
- 近肾FEVAR使用ZFEN平台与近肾/肾下FEVAR相比,免于再干预和总生存无统计学显著差异。
- 研究因样本量和低事件率检验效能不足,无法证明真正等效。
- 再干预率仍较高,主要由术后2-3年内内漏导致。
- 长期结局因大量失访而不确定,晚期内漏、破裂和再干预可能被低估。
研究设计与样本
- 单中心学术转诊中心回顾性队列研究,纳入2012年4月至2017年4月所有ZFEN修复病例。
- 排除使用改良移植物或EVAR挽救的病例,共纳入90例(近肾26例,近肾/肾下64例)。
- 比较近肾AAA与近肾/肾下AAA的FEVAR结局,随访至8年。
- 主要结局为免于再干预和总生存。
主要发现
- 8年估计免于再干预率:近肾组67.4% vs 近肾/肾下组57.6%(P=0.93)。
- 8年总生存率:近肾组35.9% vs 近肾/肾下组42.3%(P=0.46)。
- 总体25例(27.8%)需要再干预,近肾组7例(26.9%),近肾/肾下组18例(28.1%)。
- 再干预最常见原因为内漏。
临床怎么用
- 近肾FEVAR使用ZFEN平台的中远期结局与近肾/肾下FEVAR无显著差异,但需注意研究效能不足。
- 术后2-3年内应重点监测内漏,再干预率较高。
- 长期随访至关重要,因失访可能导致晚期事件被低估。
局限性
- 样本量小(90例),事件率低,检验效能不足无法证明等效性。
- 大量失访,长期结局不确定,晚期内漏、破裂和再干预可能被低估。
- 回顾性单中心研究,早期经验可能存在学习曲线影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Zenith Fenestrated (ZFEN) platform is commercially available in the United States for fenestrated endovascular aortic repair (FEVAR) in infrarenal abdominal aortic aneurysms (AAAs) with neck lengths of ≥4 mm. However, ZFEN has been used outside manufacturer instructions for the use of AAA with shorter necks or more proximal extents. Long-term data characterizing ZFEN results in these real-world applications are limited. We describe the mid- to long-term outcomes of our early experience using ZFEN for FEVAR in the pararenal segment. METHODS: We reviewed all ZFEN repairs performed between April 2012 and April 2017 at an academic referral center. Cases done using modified grafts or for EVAR salvage were excluded. Results up to 8 years of follow-up using ZFEN were compared between FEVAR for pararenal AAA versus juxta/infrarenal AAA. Primary outcomes included freedom from reintervention and overall survival. RESULTS: There were 90 cases included (26 pararenal, 64 juxta/infrarenal). At 8 years, estimated freedom from reintervention was 67.4% versus 57.6% (P = 0.93), while overall survival was 35.9% versus 42.3% (P = 0.46) in the pararenal and juxta/infrarenal groups, respectively. In the series overall, 25 patients (27.8%) required reintervention, with seven (26.9%) in the pararenal group versus 18 in the juxta/infrarenal group (28.1%). Reinterventions were most often performed for endoleaks. CONCLUSION: Pararenal FEVAR using the ZFEN platform demonstrated no statistically significant differences in freedom from reintervention or overall survival compared to juxta/infrarenal FEVAR. However, the study is underpowered to prove true equivalence due to sample size and low event rates. Reintervention rates remain high, primarily due to endoleaks within the first 2-3 years. While few aneurysm-related deaths were observed, long-term outcomes remain uncertain due to substantial loss to follow-up. Consequently, late endoleaks, ruptures, and reinterventions may be underestimated. These data suggest that pararenal ZFEN outcomes do not statistically differ from juxta/infrarenal outcomes, though uncertainty remains, requiring ongoing long-term surveillance.
引用
- Basu R, Davis J, Hughes A, et al. Mid- to Long-Term Outcomes of an Early Experience with Fenestrated Endovascular Aortic Repair for Pararenal Versus Juxtarenal and Infrarenal Aneurysms. Ann Vasc Surg. 2026. PMID: 42567305. doi:10.1016/j.avsg.2026.07.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。